[Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
OBJECTIVE
The increasing evidence of the benefits of neonatal screening for cystic fibrosis (CF) indicates that this procedure could soon be implemented throughout France. The screening strategy currently used involves the detection of infants with elevated levels of immunoreactive trypsinogen (IRT) (approximately 1% of the population), followed by the detection of CFTR gene mutations. However, genetic analysis has certain drawbacks, the most important of which being the management of heterozygotes, and in France the requirement by law of previous informed consent. In cases of CF, pancreatic alterations are already present in utero. A previous study has demonstrated the value of pancreatitis-associated protein (PAP) as a screening test for CF, and has indicated that a feasible two-stage strategy could involve the following: 1) selection of infants with elevated PAP levels; 2) in this group of infants, subsequent detection of those with elevated IRT levels for direct CF diagnosis by the sweat test thereby avoiding the use of genetic analysis. The study aim was to evaluate this strategy in a large number of neonates.


RESULTS
The aforementioned strategy was evaluated in a prospective study involving 47,213 infants in the Provence region of France. In infants with a PAP > 7.5 ng/mL (1.28%), 176 had an elevated IRT level > 700 ng/mL (0.37%). In this limited population sample (0.37% of the total), the sweat test diagnosed five cases of CF. A sixth case involving the monozygous twin of an infant with diagnosed CF remained undetected, probably because of a registration error. Genetic analysis confirmed the diagnosis, and also detected another case in an infant with two CFTR mutations but with a normal phenotype at 20 months of age. As the observed incidence was similar to that which had previously been reported, and as no further case was subsequently detected two years after the end of the study, this indicated that the sensitivity of this screening strategy was satisfactory. Its specificity makes the direct diagnosis of CF cases by the sweat test feasible, without further selection by genetic analysis.


CONCLUSIONS
The PAP/IRT technique for CF detection seems to be suitable for mass screening, without the drawbacks of genetic testing.
Unité 315 Inserm, 46, boulevard de la Gaye, 13009 Marseille, France.
S
S
Barthellemy
N
N
Maurin
M
M
Roussey
C
C
Férec
S
S
Murolo
P
P
Berthézène
J L
JL
Iovanna
J C
JC
Dagorn
J
J
Sarles
D000209:Acute-Phase Proteins / Q000378:metabolism*; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D003550:Cystic Fibrosis / Q000097:blood* / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay / Q000592:standards; D005240:Feasibility Studies; D005602:France / Q000453:epidemiology; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D007231:Infant, Newborn; D037181:Lectins, C-Type; D009154:Mutation / Q000235:genetics; D015997:Neonatal Screening / Q000379:methods* / Q000592:standards; D000073718:Pancreatitis-Associated Proteins; D018579:Patient Selection; D015397:Program Evaluation; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D014362:Trypsinogen / Q000097:blood*
D000209:Acute-Phase Proteins; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C505032:CFTR protein, human; D037181:Lectins, C-Type; D000073718:Pancreatitis-Associated Proteins; C000612141:REG3A protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D014362:Trypsinogen